Table A2.
hSBA GMTs, GMRs and seroresponse rates against the MenC vaccine reference strain (all time points)
| Value (95% CI) |
|||
|---|---|---|---|
| 2_MenACWY (N = 30) | 1_MenACWY (N = 30) | 1_MenC (N = 30) | |
| Visit 3 GMT | 19.7 (12.0; 32.5) | 2.1 (1.9; 2.4) | 2.6 (1.9; 3.5) |
| Visit 4 GMT | 279.9 (204.0; 384.1) | 23.9 (14.7; 39.0) | 35.6 (23.5; 53.9) |
| Visit 4/Visit 3 GMR | - | 11.3 (7.0; 18.4) | 13.8 (8.2; 23.2) |
| Visit 7 GMT | 3.5 (2.7; 4.7) | 3.9 (2.4; 6.2) | 4.3 (2.8; 6.6) |
| Visit 8 GMT | 554.1 (352.3; 871.5) | 956.0 (580.1; 1575.6) | 1935.4 (1321.3; 2834.8) |
| Visit 8/Visit 7 GMR | 156.6 (99.1; 247.6) | 247.6 (171.4; 357.6) | 449.2 (291.2; 692.8) |
| Seroresponse rate | - | 83.3% (65.3; 94.4) | 82.8% (64.2; 94.2) |
hSBA, serum bactericidal activity assay with human complement; 95% CI, 95% confidence interval; GMT, geometric mean titer, GMR, geometric mean ratio; N, number of children; Group 2_MenACWY, MenACWY-CRM vaccination at 6–8 and 12 months of age; Group 1_MenACWY, MenACWY-CRM vaccination at 12 months of age; Group 1_MenC, MenC-CRM vaccination at 12 months of age.
Note: Seroresponse was defined for children with Visit 3 hSBA titer <1:4 as an hSBA titer ≥1:8 at Visit 4, and for children with Visit 3 hSBA titer ≥1:4 as a ≥ 4-fold raise in hSBA titers at Visit 4.
For group 1_MenC, N = 29 for the seroresponse rate.